(ABBV) - Analyzing AbbVie's Short Interest
Absence of Black Box Warning For Bristol Myers' Schizophrenia Treatment Could Enhance Alzheimer's Psychosis Potential
Leerink Partners Maintains AbbVie(ABBV.US) With Hold Rating
AbbVie (ABBV.US) seeks expedited approval in the usa for Teliso-V for the treatment of non-small cell lung cancer.
Biopharmaceutical company AbbVie (ABBV.USA) announced on Friday that it has applied to the United States Food and Drug Administration for accelerated approval of its antibody-drug conjugate for a certain type of lung cancer patients. The company stated that the application covers telisotuzumab vedotin or teliso-V, for the treatment of adult patients with previously treated, locally advanced or metastatic epidermal growth factor receptor wild-type, non-squamous non-small cell lung cancer with c-Met protein overexpression.
AbbVie's Parkinson's Drug Tavapadon: A Market Perform Rating Amidst Competitive Landscape and Clinical Trials
AbbVie Seeks Accelerated FDA OK of Teliso-V in Non-Small Cell Lung Cancer
Express News | Abbvie Submits Biologics License Application to the FDA for Telisotuzumab Vedotin (Teliso-V) in Previously Treated Non-Small Cell Lung Cancer
AbbVie Submits Biologics License Application to the FDA for Telisotuzumab Vedotin (Teliso-V) in Previously Treated Non-Small Cell Lung Cancer
Investors Heavily Search AbbVie Inc. (ABBV): Here Is What You Need to Know
BMO Capital Maintains AbbVie(ABBV.US) With Buy Rating, Maintains Target Price $214
Analysts Are Bullish on Top Healthcare Stocks: AbbVie (ABBV), ACADIA Pharmaceuticals (ACAD)
Bristol Myers Stock Jumps. Why FDA Approval for Its Schizophrenia Drug Is Ground Breaking. -- Barrons.com
Here's How Much You Would Have Made Owning AbbVie Stock In The Last 10 Years
Press Release: OSE Immunotherapeutics Announces Historic H1 2024 Results and Provides Corporate Update
AbbVie's Parkinson's disease drug achieved primary endpoint in late-stage trial.
On September 26, Glehan.com reported that abbvie announced on Thursday that Tavapadon met the primary endpoint in the pivotal phase 3 clinical trial for treating early-stage Parkinson's disease patients.
AbbVie: Tavapadon Meets Primary, Secondary Endpoints In Phase 3 Trial In Early Parkinson's Disease
Express News | Abbvie Inc - Tempo-1 Trial Evaluated Two Fixed Doses of Tavapadon
Express News | Abbvie Inc - Phase 3 Tempo-2 Trial Results Expected by End of 2024
Express News | Abbvie Inc - Trial Meets Key Secondary Endpoint in Mds-Updrs Part II Score
Express News | Abbvie: Tavapadon Met Primary Endpoint in Pivotal Phase 3